N Loman

Summary

Affiliation: University Hospital
Country: Sweden

Publications

  1. ncbi Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer
    N Loman
    Department of Oncology, Lund University Hospital, Sweden
    J Natl Cancer Inst 93:1215-23. 2001
  2. pmc Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status
    Niklas Loman
    Department of Oncology, Lund University Hospital, Lund, Sweden
    Breast Cancer Res 5:R175-86. 2003
  3. ncbi Prognosis and clinical presentation of BRCA2-associated breast cancer
    N Loman
    Jubileum Institute, Department of Oncology, Lund University Hospital, SE 221 85, Lund, Sweden
    Eur J Cancer 36:1365-73. 2000
  4. ncbi [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer]
    Niklas Loman
    Onkologiska kliniken, Universitetssjukhuset, SE221 85 Lund, Sweden
    Lakartidningen 101:2172-7. 2004
  5. ncbi Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers
    O Johannsson
    Department of Oncology, University Hospital Lund, Sweden
    Eur J Cancer 35:1248-57. 1999
  6. ncbi One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden
    S Malander
    Department of Oncology, The Jubileum Institution, University Hospital, 221 85 Lund, Sweden
    Eur J Cancer 40:422-8. 2004
  7. doi Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
    J Bjohle
    Department of Oncology, Karolinska Institutet and University Hospital, Radiumhemmet, 171 76 Stockholm, Sweden
    Breast Cancer Res Treat 139:751-8. 2013
  8. ncbi Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report
    A Koul
    Department of Oncology and Gynecological Oncology, University Hospital, Lund, S-221 85, Sweden
    Gynecol Oncol 80:399-402. 2001
  9. doi Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
    T Hatschek
    Breast Sarcoma Unit, Department of Oncology, Karolinska University Hospital, Karolinska Institutet, 17176, Stockholm, Sweden
    Breast Cancer Res Treat 131:939-47. 2012
  10. pmc Molecular classification of familial non-BRCA1/BRCA2 breast cancer
    Ingrid Hedenfalk
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:2532-7. 2003

Collaborators

Detail Information

Publications12

  1. ncbi Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer
    N Loman
    Department of Oncology, Lund University Hospital, Sweden
    J Natl Cancer Inst 93:1215-23. 2001
    ..This study was undertaken to provide reliable population-based estimates of genetic influence and to characterize the nature and prevalence of BRCA1 and BRCA2 germline mutations in early-onset breast cancer...
  2. pmc Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status
    Niklas Loman
    Department of Oncology, Lund University Hospital, Lund, Sweden
    Breast Cancer Res 5:R175-86. 2003
    ..In families with a BRCA1 or a BRCA2 mutation, individual carrier status predicts the risk of breast cancer. In relatives of cases where both BRCA1 and BRCA2 mutations are excluded, the risk remains undetermined...
  3. ncbi Prognosis and clinical presentation of BRCA2-associated breast cancer
    N Loman
    Jubileum Institute, Department of Oncology, Lund University Hospital, SE 221 85, Lund, Sweden
    Eur J Cancer 36:1365-73. 2000
    ..Data presented here needs to be taken into account when counselling healthy carriers of BRCA2 germ line mutations...
  4. ncbi [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer]
    Niklas Loman
    Onkologiska kliniken, Universitetssjukhuset, SE221 85 Lund, Sweden
    Lakartidningen 101:2172-7. 2004
    ..Further studies are warranted to elucidate the efficacy of chemoprevention in women at a very high risk of breast cancer, e.g. mutation carriers of BRCA1 and BRCA2...
  5. ncbi Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers
    O Johannsson
    Department of Oncology, University Hospital Lund, Sweden
    Eur J Cancer 35:1248-57. 1999
    ..Our data suggest that apart from breast and ovarian cancer, the incidence of other cancer types do not appear to be greatly increased in BRCA1- and BRCA2-associated families and does not warrant specific clinical follow-up in carriers...
  6. ncbi One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden
    S Malander
    Department of Oncology, The Jubileum Institution, University Hospital, 221 85 Lund, Sweden
    Eur J Cancer 40:422-8. 2004
    ....
  7. doi Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
    J Bjohle
    Department of Oncology, Karolinska Institutet and University Hospital, Radiumhemmet, 171 76 Stockholm, Sweden
    Breast Cancer Res Treat 139:751-8. 2013
    ..These results suggest that this factor is a useful serum marker. In the present material, a prognostic value of CA 15-3 could not be proven. ..
  8. ncbi Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report
    A Koul
    Department of Oncology and Gynecological Oncology, University Hospital, Lund, S-221 85, Sweden
    Gynecol Oncol 80:399-402. 2001
    ..CONCLUSIONS: To the best of our knowledge the molecular genetic profile of these tumors is not found in the literature and it is suggested that such analyses could provide some insight for a better understanding of this rare phenomenon...
  9. doi Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
    T Hatschek
    Breast Sarcoma Unit, Department of Oncology, Karolinska University Hospital, Karolinska Institutet, 17176, Stockholm, Sweden
    Breast Cancer Res Treat 131:939-47. 2012
    ..In this trial with limited power, the addition of capecitabine to epirubicin and paclitaxel as first-line treatment did not translate into clinically relevant improvement of the outcome...
  10. pmc Molecular classification of familial non-BRCA1/BRCA2 breast cancer
    Ingrid Hedenfalk
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:2532-7. 2003
    ..These findings illustrate that, when gene expression-based classifications are used, BRCAx families can be grouped into homogeneous subsets, thereby potentially increasing the power of conventional genetic analysis...
  11. ncbi Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors
    Mervi Laakso
    Department of Pathology, Seinajoki Central Hospital, Seinajoki, Finland
    Mod Pathol 18:1321-8. 2005
    ..These results suggest that CK5/14-positive sporadic breast cancers arise from glandularly committed progenitor cells rather than true CK8/18-negative basal cells...
  12. ncbi Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing
    Helena Jernstrom
    Department of Oncology, Clinical Sciences, Lund University Hospital, SE 221 85 Lund, Sweden
    Eur J Cancer 41:2312-20. 2005
    ..Each year of OC use prior to age 20 years conferred a significantly increased risk for early-onset breast cancer, while there was no risk associated with use after age 20 years...